讲义课件说明教案shanghaifinal mcc佛anderson.pptxVIP

Multiple Myeloma Kenneth C. Anderson, M.D. Jerome Lipper Multiple Myeloma Center Dana-Farber Cancer Institute Harvard Medical School ;Conflict of Interest: Kenneth C. Anderson, M.D. Consultancy: Celgene, Onyx, Sanofi Aventis, and Gilead Scientific Founder: Acetylon, Oncopep;Criteria for Diagnosis of Myeloma;Prevalence of MGUS;27%;;Risk Stratification Based on Bone Marrow Plasmacytosis, Serum M Protein, and Serum Immunoglobulin FLC Ratio ; Inclusion Criteria PCs BM ≥ 10% plus M-protein ≥ 30 g/L or PCs BM ≥ 10% or M-protein ≥ 30 g/L but BM aPC/nPC ≥ 95% plus immunoparesis;QuiRedex: Study Design;Len-Dex vs No Treatment: TTP to Active Disease (n = 119) ITT analysis ;Lenalidomide + Dex;Diagnosis of Active MM In Asymptomatic Patients (IMWG Stockholm June 2013);Smoldering Multiple Myeloma;Integration of Novel Therapy Into Myeloma Management; Chromosomes and Prognosis in Multiple Myeloma;Salvage Therapy for Relapsed/Refractory MM;Overview of Phase III Trials with Len and Bortezomib in Relapsed/Refractory MM;When to Consider Retreatment;Considerations in Patients With Relapsed/Refractory Myeloma;Possible Treatment Approaches for Patients with Relapse Early in the Disease Course or Indolent Relapse.;Possible Treatment Approaches for Patients with Aggressive Relapse or Relapse Late in the Disease Course.;Pomalidomide With Low-Dose Dexamethasone Relapsed and Refractory Multiple Myeloma ;A Phase III Clinical Trial of Pomalidomide with Low-Dose Dex vs High Dose Dex in Relapsed/Refractory MM;MM-005: A Phase 1 Trial of Pomalidomide, Bortezomib, and Low-Dose Dexamethasone in Relapsed or Relapsed/Refractory MM;;Phase I/II: Elotuzumab + Len + Low-Dose Dex in Rel/Ref MM (Study 1703);Phase 2 Elotuzumab Lenalidomide Low-Dose Dex in Relapsed/ Refractory MM ;Additional Targeted Therapies in Development;;VANTAGE 088: An International, Multicenter, Randomized, Double-Blind Study of Vorinostat or Placebo with Bortezomib in Relapsed MM;Bench to Bedside Translation of HDAC 6